Picture2.jpg
ASLAN Pharmaceuticals Reports First Quarter 2021 Financial Results and Provides Corporate Update
May 11, 2021 07:30 ET | ASLAN PHARMACEUTICALS LIMITED
 - Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 - Phase 2b clinical trial for ASLAN004 expected to...
Picture2.jpg
ASLAN Pharmaceuticals to Present Data on ASLAN004 at Society for Investigative Dermatology
May 05, 2021 05:22 ET | ASLAN PHARMACEUTICALS LIMITED
- ASLAN will give a poster presentation of new data from its Single Ascending Dose (SAD) study of ASLAN004, during the virtual event on 6 May, 2021 SINGAPORE, May 05, 2021 (GLOBE NEWSWIRE) --...
Picture2.jpg
ASLAN Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Corporate Update
April 22, 2021 07:51 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, April 22, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
Picture2.jpg
ASLAN Pharmaceuticals Announces Pricing of Public Offering of American Depositary Shares
March 03, 2021 00:42 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 03, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
Picture2.jpg
ASLAN Pharmaceuticals Announces Proposed Public Offering of American Depositary Shares
March 01, 2021 16:01 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, March 01, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq: ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Announces Positive Interim Data From the Multiple Ascending Dose Study of ASLAN004 in Atopic Dermatitis
March 01, 2021 06:00 ET | ASLAN PHARMACEUTICALS LIMITED
- 74% average reduction in EASI from baseline at therapeutic doses after 8 weeks. 89% of patients achieved EASI-50 and 56% achieved EASI-90 - Data supportive of ASLAN004’s potential as a novel,...
ASLAN Pharmaceuticals Announces $18 Million Private Placement
February 25, 2021 06:30 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Feb. 25, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Appoints Dr Neil Graham as Independent Director
February 18, 2021 07:00 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Feb. 18, 2021 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...
ASLAN Pharmaceuticals Opens Expansion Cohort in ASLAN004 Atopic Dermatitis Clinical Trial
January 11, 2021 05:34 ET | ASLAN PHARMACEUTICALS LIMITED
- ASLAN has completed recruitment of patients into the third, highest dose cohort of ASLAN004 in AD patients. ASLAN004 was found to be well tolerated at all dose levels - Data Monitoring...
ASLAN Pharmaceuticals to Present at Upcoming Piper Sandler Investor Conference
November 19, 2020 07:22 ET | ASLAN PHARMACEUTICALS LIMITED
SINGAPORE, Nov. 19, 2020 (GLOBE NEWSWIRE) -- ASLAN Pharmaceuticals (Nasdaq:ASLN), a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the...